Manufacturing Mastery: Scalable Aseptic Fill-Finish That Maximizes Yield

This year at CPHI Barcelona (24–26 October, 2023) we sat down with C-suite executives and HR professionals to discuss the looming talent crisis in the pharmaceutical industry. With hybrid working persisting post-pandemic and a growing skills gap, how can the pharmaceutical supply chain adjust to a changing labour force? 

Slow, unpredictable cell line development can cost you precious time, especially in early development, when timelines are tight and the pressure to deliver is high. KBI's Cell Line Development is made to flex, built to scale and proven to deliver. 

In this Connect to Frankfurt session, Séverine Fagète, VP, Cell Line Development Services at Selexis (Geneva, Switzerland), and Brandon Brino (Durham, USA), Process Development Scientist and Group Leader at KBI Biopharma, present an overview of a streamlined process for the production of bispecific molecules.  

Up to $500,000 toward your first GMP batch. Discover how!

For emerging biologics, Phase I is just the beginning. If your early data looks promising, you'll need a partner ho can handle the next steps, without forcing a complete manufacturing reset.

KBI Gannt Chart - From transfection to IND ready.

U.S. based data-driven centered on your molecule.  KBI is your trusted partner for commercial manufacturing.

KBI Biopharma and MilliporeSigma  have partnered to provide integrated end-to-end solutions for ADCs, combining expertise in process development, mAb intermediate manufacturing, bioconjugation, and bulk drug substance production.

SUREmAb preemptively navigates technical hurdles for exceptional performance, delivering high titers (up to 18 g/L) with a streamlined, lower-cost workflow. 

KBI's cell line development - powered by Selexis TranspoEase - delivers an elite, category-setting transposase-based technology that is built on the SUREtechnology platform.

Effective control of host cell protein (HCP) is crucial in biopharmaceutical production to ensure safety and regulatory compliance. Read more about KBI's use of High Resolution Mass Spectrometry for targeted quantitation of protein impurities.